Skip to content

FRANCART-DELFOSSE PHARMA: what changed

BE 0874.177.262NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
-€35,506
2024 · -€20,828-€14,678
Equity
€231,306
2024 · €266,812-€35,506
Cash
€47,054
2024 · €22,959+€24,095
Balance sheet total
€645,104
2024 · €640,868+€4,236

Largest movements

2024 to 2025
Assets
  • Receivables within one year -€33,182

    down €33,182 (-49.0%), from €67,751 to €34,569

    of which Trade receivables: -€37,646

  • Cash +€24,095

    up €24,095 (+105%), from €22,959 to €47,054

    mainly Trade debts (+€37,000) and Depreciation (+€33,886)

  • Deferred charges and accrued income +€18,313

    up €18,313 (+28.5%), from €64,293 to €82,606

Equity and liabilities
  • Trade debts +€37,000

    up €37,000 (+22.5%), from €164,318 to €201,318

  • Profit (loss) carried forward -€35,506

    down €35,506 (-170%), from -€20,828 to -€56,334

  • Other debts +€17,880

    up €17,880 (+101%), from €17,782 to €35,662

  • Current portion of long-term debt -€17,691

    down €17,691 (-49.6%), from €35,637 to €17,945

  • Provisions +€11,618

    up €11,618 (+21.4%), from €54,176 to €65,794

Income statement
  • Staff costs +€15,111

    up €15,111 (+46.4%), from €32,581 to €47,691

  • Gross operating margin +€12,086

    up €12,086 (+9.6%), from €126,259 to €138,346

  • Provisions +€6,073

    up €6,073 (+110%), from €5,545 to €11,618

  • Financial charges +€5,926

    up €5,926 (+8.3%), from €71,578 to €77,504

  • Other operating charges -€1,639

    down €1,639 (-35.4%), from €4,630 to €2,991

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result.

Result 2024 -€20,828
Gross operating margin +€12,086
Staff costs -€15,111
Depreciation -€1,358
Provisions -€6,073
Other operating charges +€1,639
Financial income +€35
Financial charges -€5,926
Taxes +€28
Result 2025 -€35,506
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€72,886
Investment -€28,826
Financing -€19,965
Cash 2024 €22,959
Net result for the year -€35,506
Depreciation +€33,886
Stocks and contracts -€70
Receivables within one year +€33,182
Deferred charges and accrued income -€18,313
Provisions +€11,618
Trade debts +€37,000
Tax, wage and social debts -€6,791
Other debts +€17,880
Investment in fixed assets (net) -€28,826
Debts after one year -€919
Current portion of long-term debt -€17,691
Short-term financial debts -€1,355
Cash 2025 €47,054
brings cash intakes cash out
Every line side by side 54 lines
Line Code 2024 2025 Change %
Total assets 20/58 €640,868 €645,104 +€4,236 +0.7%
Fixed assets 21/28 €357,120 €352,060 -€5,060 -1.4%
Intangible fixed assets 21 €0 €0 =
Tangible fixed assets 22/27 €357,120 €352,060 -€5,060 -1.4%
Land and buildings 22 €330,918 €330,371 -€547 -0.2%
Plant, machinery and equipment 23 €23,559 €19,818 -€3,742 -15.9%
Furniture and vehicles 24 €2,643 €1,872 -€771 -29.2%
Current assets 29/58 €283,748 €293,044 +€9,296 +3.3%
Stocks and contracts in progress 3 €128,745 €128,815 +€70 +0.1%
Stocks 30/36 €128,745 €128,815 +€70 +0.1%
Amounts receivable within one year 40/41 €67,751 €34,569 -€33,182 -49.0%
Trade receivables 40 €51,539 €13,893 -€37,646 -73.0%
Other amounts receivable 41 €16,211 €20,676 +€4,465 +27.5%
Cash at bank and in hand 54/58 €22,959 €47,054 +€24,095 +105%
Deferred charges and accrued income 490/1 €64,293 €82,606 +€18,313 +28.5%
Total equity and liabilities 10/49 €640,868 €645,104 +€4,236 +0.7%
Equity 10/15 €266,812 €231,306 -€35,506 -13.3%
Contributions 10/11 €12,400 €12,400 = 0.0%
Revaluation surpluses 12 €96,498 €89,743 -€6,755 -7.0%
Reserves 13 €178,742 €185,497 +€6,755 +3.8%
Tax-exempt reserves 132 €18,750 €18,750 = 0.0%
Distributable reserves 133 €159,992 €166,747 +€6,755 +4.2%
Profit (loss) carried forward 14 -€20,828 -€56,334 -€35,506 -170%
Provisions and deferred taxes 16 €54,176 €65,794 +€11,618 +21.4%
Provisions for liabilities and charges 160/5 €54,176 €65,794 +€11,618 +21.4%
Other liabilities and charges 164/5 €54,176 €65,794 +€11,618 +21.4%
Amounts payable 17/49 €319,880 €348,003 +€28,123 +8.8%
Amounts payable after more than one year 17 €73,438 €72,519 -€919 -1.3%
Financial debts 170/4 €73,438 €72,519 -€919 -1.3%
Amounts payable within one year 42/48 €246,442 €275,484 +€29,042 +11.8%
Current portion of amounts payable after more than one year 42 €35,637 €17,945 -€17,691 -49.6%
Financial debts 43 €7,254 €5,899 -€1,355 -18.7%
Credit institutions 430/8 €7,254 €5,899 -€1,355 -18.7%
Trade debts 44 €164,318 €201,318 +€37,000 +22.5%
Suppliers 440/4 €164,318 €201,318 +€37,000 +22.5%
Taxes, remuneration and social security 45 €21,451 €14,660 -€6,791 -31.7%
Taxes 450/3 €10,987 €3,958 -€7,029 -64.0%
Remuneration and social security 454/9 €10,464 €10,701 +€237 +2.3%
Other amounts payable 47/48 €17,782 €35,662 +€17,880 +101%
Non-recurring operating income 76A €6,448 - -€6,448
Remuneration, social security and pensions 62 €32,581 €47,691 +€15,111 +46.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €32,528 €33,886 +€1,358 +4.2%
Provisions for liabilities and charges: additions (uses and reversals) 635/8 €5,545 €11,618 +€6,073 +110%
Other operating charges 640/8 €4,630 €2,991 -€1,639 -35.4%
Gross operating margin 9900 €126,259 €138,346 +€12,086 +9.6%
Operating profit (loss) 9901 €50,975 €42,159 -€8,816 -17.3%
Financial income 75/76B €243 €278 +€35 +14.4%
Recurring financial income 75 €243 €278 +€35 +14.4%
Financial charges 65/66B €71,578 €77,504 +€5,926 +8.3%
Recurring financial charges 65 €71,578 €77,504 +€5,926 +8.3%
Profit (loss) for the period before taxes 9903 -€20,361 -€35,067 -€14,706 -72.2%
Income taxes 67/77 €467 €439 -€28 -6.0%
Profit (loss) for the period 9904 -€20,828 -€35,506 -€14,678 -70.5%
Profit (loss) for the period to be appropriated 9905 -€20,828 -€35,506 -€14,678 -70.5%

Value

latest balance sheet 30-06-2025 · indication, not a valuation or advice

Value of the equity

Indication, not a valuation or advice
€231,306 to €231,306

Midpoint €231,306 · adjusted equity only

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Worked out with Checked's starting values, not your estimate. Change the assumptions and the value follows.

Adjusted equity €231,306
Indication €231,306

Adjusted equity

balance sheet 30-06-2025
Equity (10/15)
€231,306
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€231,306

Capitalised earnings

net result for the year (9904)
2025
-€35,506
2024
-€20,828
excluding non-recurring income and charges
-€27,276
2023
€29,500
excluding non-recurring income and charges
€23,313
2022
€22,656
excluding non-recurring income and charges
€23,306
2021
€46,166
Average result, excluding non-recurring income and charges
-€13,156
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
not meaningful, as the average result is zero or negative

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 30 June 2024 and 30 June 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 20 November 2026 via checked.be.